0 52

Cited 0 times in

Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author성진실-
dc.contributor.author안상훈-
dc.contributor.author원종윤-
dc.contributor.author이혜원-
dc.contributor.author정규식-
dc.contributor.author한광협-
dc.date.accessioned2018-07-20T08:07:48Z-
dc.date.available2018-07-20T08:07:48Z-
dc.date.issued2017-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160860-
dc.description.abstractPURPOSE: It is unclear whether the efficacy and safety of concurrent chemoradiation therapy (CCRT) and transarterial radioembolization (TARE) with 90Y are comparable in patients with locally advanced hepatocellular carcinoma. METHODS AND MATERIALS: In total, 209 treatment-naive patients with stage B or C cancer according to the Barcelona Clinic Liver Cancer classification who were treated with TARE or CCRT were analyzed. Propensity scores were calculated and matched at a 1:1 ratio for TARE versus CCRT using age, tumor size, tumor number, portal vein thrombosis, and Barcelona Clinic Liver Cancer staging. In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy). Overall survival, freedom from progression, tumor response, and complication rate were compared between the TARE and CCRT groups. RESULTS: Among 209 patients, 124 (62 undergoing TARE and 62 undergoing CCRT) were selected after propensity score matching. Overall survival (TARE vs CCRT, 14.0 months vs 13.2 months, P=.435) and freedom from progression (6.9 months vs 7.8 months, P=.437) were comparable between the 2 groups. Objective response rates at 1 month after treatment were higher for CCRT than for TARE (46.8% vs 16.1%, P<.001), while objective response rates at 3 months were significantly higher for TARE than for CCRT (39.3% vs 21.4%, P=.04). There was no significant difference in long-term response rates (at 6 months and 1 year) between the 2 groups. The CCRT group experienced a higher rate of curative resection or liver transplantation after treatment than the TARE group, although the statistical significance was marginal (24.2% vs 11.3%, P=.060). Treatment-related complications were less frequent after TARE than after CCRT. CONCLUSIONS: Both treatments yielded comparable survival rates and long-term response rates in patients with intermediate- or advanced-stage hepatocellular carcinoma. The role of these modalities as a bridge to curative therapy requires further investigation.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science Inc.-
dc.relation.isPartOfInternational Journal of Radiation Oncology Biology Physics-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAge Factors-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntimetabolites, Antineoplastic/administration & dosage-
dc.subject.MESHCarcinoma, Hepatocellular/mortality-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHCarcinoma, Hepatocellular/therapy*-
dc.subject.MESHChemoembolization, Therapeutic/adverse effects-
dc.subject.MESHChemoembolization, Therapeutic/methods*-
dc.subject.MESHChemoembolization, Therapeutic/mortality-
dc.subject.MESHChemoradiotherapy/adverse effects-
dc.subject.MESHChemoradiotherapy/methods*-
dc.subject.MESHChemoradiotherapy/mortality-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/mortality-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPortal Vein-
dc.subject.MESHPropensity Score-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTumor Burden-
dc.subject.MESHVenous Thrombosis-
dc.subject.MESHYttrium Radioisotopes/therapeutic use-
dc.titleTransarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJeong Eun Song-
dc.contributor.googleauthorKyu Sik Jung-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorKijun Song-
dc.contributor.googleauthorJong Yun Won-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.1016/j.ijrobp.2017.05.049-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA01956-
dc.contributor.localIdA02226-
dc.contributor.localIdA02443-
dc.contributor.localIdA03318-
dc.contributor.localIdA03578-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid28871990-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0360301617309872-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameWon, Jong Yun-
dc.contributor.alternativeNameLee, Hye Won-
dc.contributor.alternativeNameJung, Kyu Sik-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorWon, Jong Yun-
dc.contributor.affiliatedAuthorLee, Hye Won-
dc.contributor.affiliatedAuthorJung, Kyu Sik-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.citation.volume99-
dc.citation.number2-
dc.citation.startPage396-
dc.citation.endPage406-
dc.identifier.bibliographicCitationInternational Journal of Radiation Oncology Biology Physics, Vol.99(2) : 396-406, 2017-
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실)

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.